These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24938674)

  • 1. Should health insurers target prevention of cardiovascular disease? A cost-effectiveness analysis of an individualised programme in Germany based on routine data.
    Aljutaili M; Becker C; Witt S; Holle R; Leidl R; Block M; Brachmann J; Silber S; Bestehorn K; Stollenwerk B
    BMC Health Serv Res; 2014 Jun; 14():263. PubMed ID: 24938674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of the cardiovascular disease prevention programme 'KardioPro' initiated by a German sickness fund: a time-to-event analysis of routine data.
    Witt S; Leidl R; Becker C; Holle R; Block M; Brachmann J; Silber S; Stollenwerk B
    PLoS One; 2014; 9(12):e114720. PubMed ID: 25486421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The excess health care costs of KardioPro, an integrated care program for coronary heart disease prevention.
    Becker C; Holle R; Stollenwerk B
    Health Policy; 2015 Jun; 119(6):778-86. PubMed ID: 25656962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a mindfulness-based mental health promotion program: economic evaluation of a nonrandomized controlled trial with propensity score matching.
    Müller G; Pfinder M; Schmahl C; Bohus M; Lyssenko L
    BMC Public Health; 2019 Oct; 19(1):1309. PubMed ID: 31623597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
    Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
    Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease.
    Müller-Riemenschneider F; Damm K; Meinhard C; Bockelbrink A; Vauth C; Willich SN; Greiner W
    GMS Health Technol Assess; 2009 Dec; 5():Doc16. PubMed ID: 21289903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
    Basu S; Bendavid E; Sood N
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):541-51. PubMed ID: 26555122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.
    Pandya A; Weinstein MC; Salomon JA; Cutler D; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):25-32. PubMed ID: 24425701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].
    Claes C; Mittendorf T; Grond M; von der Schulenburg JM
    Med Klin (Munich); 2008 Nov; 103(11):778-87. PubMed ID: 19165429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of drug-eluting stents in acute myocardial infarction patients in Germany: results from administrative data using a propensity score-matching approach.
    Bäumler M; Stargardt T; Schreyögg J; Busse R
    Appl Health Econ Health Policy; 2012 Jul; 10(4):235-48. PubMed ID: 22574616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
    Blake GJ; Ridker PM; Kuntz KM
    Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.
    Icks A; Rathmann W; Haastert B; Gandjour A; Holle R; John J; Giani G;
    Diabet Med; 2007 May; 24(5):473-80. PubMed ID: 17381502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The PreFord Study. A prospective cohort study to evaluate the risk of a cardiovascular event (overall-collective) as well as a prospective, randomized, controlled, multicentre clinical intervention study (high-risk-collective) on primary prevention of cardiovascular diseases in the Ford Motor Company employees in Germany].
    Gysan DB; Latsch J; Bjarnason-Wehrens B; Albus C; Falkowski G; Herold G; Mey E; Heinzler R; Montiel G; Schneider CA; Stützer H; Türk S; Weisbrod M; Predel HG
    Z Kardiol; 2004 Feb; 93(2):131-6. PubMed ID: 14963679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.